Orchestra BioMed Holdings (Orchestra BioMed Holdings) Debt-to-EBITDA : -0.03 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Orchestra BioMed Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Orchestra BioMed Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.65 Mil. Orchestra BioMed Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.04 Mil. Orchestra BioMed Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was $-49.64 Mil. Orchestra BioMed Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.03.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Orchestra BioMed Holdings's Debt-to-EBITDA or its related term are showing as below:

OBIO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.51 Med: -0.31 Max: -0.03
Current: -0.03

During the past 4 years, the highest Debt-to-EBITDA Ratio of Orchestra BioMed Holdings was -0.03. The lowest was -0.51. And the median was -0.31.

OBIO's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.37 vs OBIO: -0.03

Orchestra BioMed Holdings Debt-to-EBITDA Historical Data

The historical data trend for Orchestra BioMed Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orchestra BioMed Holdings Debt-to-EBITDA Chart

Orchestra BioMed Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

-0.51

-0.26

-0.37

-0.03

Orchestra BioMed Holdings Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial						-0.30	-0.26	-0.23	-0.20	-0.03

Competitive Comparison of Orchestra BioMed Holdings's Debt-to-EBITDA

For the Biotechnology subindustry, Orchestra BioMed Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Orchestra BioMed Holdings's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orchestra BioMed Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Orchestra BioMed Holdings's Debt-to-EBITDA falls into.

Orchestra BioMed Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Orchestra BioMed Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.649	+	1.038)	/	-51.219
	=	-0.03

Orchestra BioMed Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.649	+	1.038)	/	-49.636
	=	-0.03

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Orchestra BioMed Holdings (NAS:OBIO) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Orchestra BioMed Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Orchestra BioMed Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Orchestra BioMed Holdings (Orchestra BioMed Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orchestra BioMed Holdings Inc (NAS:OBIO) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

150 Union Square Drive,, New Hope, PA, USA, 18938

Website

https://www.orchestrabiomed.com

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. Orchestra BioMed's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Executives

George Papandreou	officer: See Remarks	C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Eric S Fain	director	ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN MN
Jason Aryeh	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
David P Hochman	director, officer: See Remarks	15 WESTON HILL RD., RIVERSIDE CT 06878
Joshua Aiello	officer: Principal Accounting Officer	150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Yuval Mika	officer: See Remarks	150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Pamela Ann Connealy	director	320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Darren Sherman	director, officer: See Remarks	C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Rose Eric A Md	director	161 FORT WASHINGTON AVENUE, 7TH FLOOR, NEW YORK NY 10032
Andrew Lawrence Taylor	officer: Chief Financial Officer	C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BLVD, 3RD FLOOR, FT. LAUDERDALE FL 33301
William Reed Little	officer: See Remarks	C/O ORCHESTRA BIOMED HOLDINGS, INC., 150 UNION SQUARE DRIVE, NEW HOPE PA 18938
Plc Medtronic	10 percent owner	20 ON HATCH, LOWER HATCH STREET, DUBLIN L2 2
Michael Kaswan	officer: Chief Financial Officer	KBL HEALTHCARE ACQUISITION CORP II, 645 MADISON AVENUE, NEW YORK NY 10022
Geoffrey Wade Smith	director	6740 SHADY OAK ROAD, EDEN PRAIRIE MN 55344
Rtw Investments, Lp	10 percent owner	40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014